Helminth-Based Product and the Microbiome of Mice with Lupus

Neuman, Hadar; Mor, Hadar; Bashi, Tomer; Givol, Or; Watad, Abdulla; Shemer, Asaf; Volkov, Alexander; Barshack, Iris; Fridkin, Mati; Shoenfeld, Yehuda; Koren, Omry

doi:10.1128/msystems.00160-18

Cited by 22 publications

(6 citation statements)

References 40 publications

(46 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, targeting the gut microbiota with drugs may be one of the mechanisms for treating SLE. For instance, treatment with a conjugate of tuftsin and phosphorylcholine (termed TPC) improved both immune and disease parameters of SLE, which was accompanied by a reduced abundance of Akkermansia and correlated with the clinical and serological parameters of lupus and an increased abundance of Bifidobacterium ; Turicibacter; unclassified Mogibacteriaceae; unclassified Clostridiaceae ; Adlercreutzia ; Allobaculum ; and Anaeroplasma [73]. Oral antibiotic administration during active SLE disease might reshape the gut microbiota, remove harmful Lachnospiraceae, increase the relative abundance of Lactobacillus spp., attenuate SLE-like disease in lupus-prone mice termed MRL/lpr mice, and ameliorate systemic autoimmunity and kidney histopathology when given after disease onset [47].…”

Section: The Gut Microbiota and Autoimmune Diseasesmentioning

confidence: 99%

The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases

Liu

Cao

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

The human gut-resident commensal microbiota is a unique ecosystem associated with various bodily functions, especially immunity. Gut microbiota dysbiosis plays a crucial role in autoimmune disease pathogenesis as well as in bowel-related diseases. However, the role of the gut microbiota, which causes or influences systemic immunity in autoimmune diseases, remains elusive. Aryl hydrocarbon receptor, a ligand-activated transcription factor, is a master moderator of host-microbiota interactions because it shapes the immune system and impacts host metabolism. In addition, treatment optimization while minimizing potential adverse effects in autoimmune diseases remains essential, and modulation of the gut microbiota constitutes a potential clinical therapy. Here, we present evidence linking gut microbiota dysbiosis with autoimmune mechanisms involved in disease development to identify future effective approaches based on the gut microbiota for preventing autoimmune diseases.

show abstract

Section: The Gut Microbiota and Autoimmune Diseasesmentioning

confidence: 99%

The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases

Liu

Cao

et al. 2019

Journal of Immunology Research

View full text Add to dashboard Cite

show abstract

“…Moreover, butyrate suppresses inducible nitric oxide synthase (iNOS) synthesis in the gut by activating PPAR-γ-signaling in colonocytes, thus preserving epithelial hypoxia and limiting the growth of nitrate respiration-dependent dysbiotic to maintain gut homeostasis ( 28 , 29 ). A recent study ( 30 ) demonstrated the effectiveness of helminth-derived tuftsin and phosphorylcholine for treating mice with lupus and demonstrated its association with an alteration in gut microbiota. In their study, butyrate-producing bacteria were associated with the amelioration of disease following treatment.…”

Section: Discussionmentioning

confidence: 99%

Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice

et al. 2020

Front. Nutr.

View full text Add to dashboard Cite

Gut microbiota has a strong influence on the onset and development of systemic lupus erythematosus (SLE), and several studies have demonstrated the effectiveness of microbiota-derived butyrate to ameliorate SLE. However, the roles of butyrate on gut microbiota in SLE are not understood. Using MRL/lpr lupus-prone mice, we examined gut microbiota profiles after butyrate treatment by 16S rRNA sequencing. Alterations in intestinal microbiome in mice with lupus-like disease were mainly characterized by a reduction in microbial diversity, with an increased abundance of Bacteroidetes and a decrease of Firmicutes. Treatment of lupus-prone mice with butyrate resulted in increased abundance of Firmicutes ( P = 0.003), Clostridia ( P = 0.005), Clostridiales ( P = 0.005), Lachnospiraceae ( P = 0.009), Ruminococcaceae ( P = 0.021), Peptostreptococcaceae ( P = 0.021), Ruminiclostridium ( P = 0.016), Oscillibacter ( P = 0.048), Romboutsia ( P = 0.025), Lachnoclostridium ( P = 0.012), Coprococcus ( P = 0.015), Ruminococcus ( P = 0.011), Clostridium leptum ( P < 0.05), and Dorea_spp . ( P = 0.019), and a reduced proportion of Bacteroidetes ( P = 0.004), Bacteroidia ( P = 0.004), and Bacteroidales ( P = 0.004). Further, butyrate supplementation could ameliorate kidney damage. Overall, this study suggests that gut microbiota alterations occur in MRL/lpr lupus-prone mice following treatment with butyrate. Butyrate supplementation ameliorated gut microbiota dysbiosis. These findings support the use of butyrate and butyrate-producing bacteria as potential treatments for SLE.

show abstract

“…TPC is well known on treatment of helminths parasite and modulation of immune response [ 77 ]. However, it was also found to modulate microflora species of the gut and suppressing the proinflammatory cytokine related in T cell activation.…”

Section: Potential Treatment For Lupus Nephritismentioning

confidence: 99%

Involvement of Gut Microbiota in SLE and Lupus Nephritis

et al. 2023

View full text Add to dashboard Cite

Lupus nephritis is a severe manifestation of systemic lupus erythematosus (SLE). It is caused by immune dysregulation and kidney inflammation. In recent findings, gut microbiota potentially acts as primary mediators to enhance immune complex deposition, complement activation, and macrophage infiltration, and led to renal inflammation. Gut inflammation, known as leaky gut, allows pathogenic bacteria to enter the blood stream to form immune complexes which deposit on the kidney. Lymphocytes and macrophages induct a proinflammatory cytokine milieu that leads to kidney inflammation. Accumulating pieces of evidence from the field of gender bias, dietary habit, alcohol, smoking and antibiotic consumption were closely related to dysbiosis of gut microbiota in SLE. However, little is known about the causes of gut microbiota dysbiosis and the potential pathway that leads to lupus nephritis (LN) flare. In this review, we will bring into deeper insight for the potential link of gut microbiota on immune system with a particular focus on renal inflammation. Moreover, we also discuss the potential novel therapies that regulate gut composition to improve or complement the current treatment of LN.

show abstract

Helminth-Based Product and the Microbiome of Mice with Lupus

Cited by 22 publications

References 40 publications

The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases

The Dynamic Interplay between the Gut Microbiota and Autoimmune Diseases

Sodium Butyrate Ameliorates Gut Microbiota Dysbiosis in Lupus-Like Mice

Involvement of Gut Microbiota in SLE and Lupus Nephritis

Contact Info

Product

Resources

About